Lyell Immunopharma (LYEL) Competitor Comparison
We are evaluating the key criteria listed to compare Lyell Immunopharma (LYEL) against its competitors in the Biotechnology industry.
Market Capitalization
150 / 368Gross Profits
50 / 278Total Revenue
125 / 300EBITDA
273 / 337Free Cashflow
258 / 352Quick Ratio
38 / 357Earnings per Share
98 / 359Dividend yield
0 / 6Total Cash
52 / 358Performance 3 years
321 / 368Performance 5 years
320 / 368Performance 10 years
285 / 368Linearity 3 years
273 / 368Linearity 5 years
273 / 368Linearity 10 years
243 / 367Total Rank
186 / 368Dividend Rank
192 / 368Valuation Rank
27 / 368Piotroski Rank
166 / 368Muliplier Rank
145 / 368Linearity 3 years - LYEL ranking 273 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.